OnKure is a clinical-stage biopharma company developing precision medicines targeting validated cancer drivers.
OnKure Therapeutics has raised $150.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2026.
OnKure Therapeutics's investors include RA Capital Management, BlackRock, Cormorant Asset Management, Vivo Capital, StepStone Group.
OnKure Therapeutics is headquartered in Boulder, United States.
OnKure is a clinical-stage biopharma company developing precision medicines targeting validated cancer drivers.
OnKure Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OnKure Therapeutics — Funding & Investors." VCBacked, March 27, 2026, https://www.vcbacked.co/company/onkure-therapeutics. Accessed November 12, 2026.
VCBacked. (2026). OnKure Therapeutics — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/onkure-therapeutics
{{cite web |title=OnKure Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/onkure-therapeutics |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at OnKure Therapeutics? Request a listing update